CN105189506A - 用于治疗寄生虫疾病的化合物和组合物 - Google Patents

用于治疗寄生虫疾病的化合物和组合物 Download PDF

Info

Publication number
CN105189506A
CN105189506A CN201380065714.4A CN201380065714A CN105189506A CN 105189506 A CN105189506 A CN 105189506A CN 201380065714 A CN201380065714 A CN 201380065714A CN 105189506 A CN105189506 A CN 105189506A
Authority
CN
China
Prior art keywords
phenyl
pyrazine
methyl
imidazo
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380065714.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·K·查特吉
A·S·内格尔
P·帕拉塞利
龙仕永
J·T·罗兰
P·K·米什拉
B·Ks·杨
邹斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105189506A publication Critical patent/CN105189506A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380065714.4A 2012-11-19 2013-11-18 用于治疗寄生虫疾病的化合物和组合物 Pending CN105189506A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728024P 2012-11-19 2012-11-19
US61/728,024 2012-11-19
PCT/US2013/070623 WO2014078813A1 (en) 2012-11-19 2013-11-18 Compounds and compositions for the treatment of parasitic diseases

Publications (1)

Publication Number Publication Date
CN105189506A true CN105189506A (zh) 2015-12-23

Family

ID=49667633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380065714.4A Pending CN105189506A (zh) 2012-11-19 2013-11-18 用于治疗寄生虫疾病的化合物和组合物

Country Status (5)

Country Link
US (1) US20150291598A1 (enExample)
EP (1) EP2920177A1 (enExample)
JP (1) JP2016500073A (enExample)
CN (1) CN105189506A (enExample)
WO (1) WO2014078813A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110168093A (zh) * 2017-09-12 2019-08-23 广州中科蓝华生物科技有限公司 一种转染细胞内寄生虫的试剂盒及其应用
CN110809577A (zh) * 2017-06-30 2020-02-18 雷沃医疗有限公司 腺苷a2a受体的调节剂

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291598A1 (en) * 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
ES2655030T3 (es) 2012-11-19 2018-02-16 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JP6675334B2 (ja) * 2014-06-25 2020-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物
US10220036B2 (en) 2014-12-23 2019-03-05 Novartis Ag Triazolopyrimidine compounds and uses thereof
CN104610229B (zh) * 2015-01-21 2017-01-18 上海皓元生物医药科技有限公司 一种是atp竞争性小分子akt抑制剂a443654的合成方法
JP2019522049A (ja) 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
CA3027246A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
EP3617207B1 (en) 2017-04-27 2023-06-28 Nihon Nohyaku Co., Ltd. Condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide
US11584744B2 (en) * 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
IL312674A (en) 2018-01-29 2024-07-01 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
GB201811695D0 (en) 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
MY200452A (en) 2018-08-21 2023-12-27 Kyorin Seiyaku Kk Bicyclic heteroaromatic ring derivative
WO2020116662A1 (ja) 2018-12-06 2020-06-11 第一三共株式会社 シクロアルカン−１，３−ジアミン誘導体
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
US11459331B2 (en) 2019-01-30 2022-10-04 Avista Pharma Solutions, Inc. Chemical compounds
PE20221318A1 (es) 2019-10-21 2022-09-08 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2024022910A1 (en) 2022-07-26 2024-02-01 Syngenta Crop Protection Ag 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-dichloro-5-phenyl]urea derivatives and similar compounds as pesticides
WO2024213651A1 (en) * 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
AR132358A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados bicíclicos de imidazo
TW202446263A (zh) * 2023-04-13 2024-12-01 瑞士商先正達農作物保護股份公司 殺真菌組成物
WO2024213653A1 (en) * 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
WO2024213650A1 (en) * 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
AR132352A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de imidazo[1,2-a]pirazina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
KR20090112732A (ko) * 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
JO3156B1 (ar) * 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
US20150291598A1 (en) * 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110809577A (zh) * 2017-06-30 2020-02-18 雷沃医疗有限公司 腺苷a2a受体的调节剂
CN110168093A (zh) * 2017-09-12 2019-08-23 广州中科蓝华生物科技有限公司 一种转染细胞内寄生虫的试剂盒及其应用
CN110168093B (zh) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 一种转染细胞内寄生虫的试剂盒及其应用

Also Published As

Publication number Publication date
JP2016500073A (ja) 2016-01-07
WO2014078813A1 (en) 2014-05-22
US20150291598A1 (en) 2015-10-15
EP2920177A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
CN105189506A (zh) 用于治疗寄生虫疾病的化合物和组合物
TWI869519B (zh) Sos1抑制劑
TWI868441B (zh) 非環氧氮呯化合物及其用途
US20240025919A1 (en) Aza-tetracyclic oxazepine compounds and uses thereof
CN102203067B (zh) Hedgehog通路调节剂
JP6298472B2 (ja) 寄生虫病の処置のための化合物および組成物
WO2023064857A1 (en) Quinoline compounds as inhibitors of kras
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
JP2025535367A (ja) ６－アザ部分を含むオキサゼピン化合物およびその使用
CN108026105B (zh) TGFβ受体拮抗剂
TW201522342A (zh) 用於治療寄生蟲疾病之化合物及組合物
JP2013501002A (ja) Ｓｙｋキナーゼ阻害剤としての化合物および組成物
KR20170075756A (ko) 카르바졸 유도체
TWI879771B (zh) 三環類化合物及其用途
JP2020537692A (ja) ヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びその使用方法
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
CN106029666B (zh) 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物
TW202216712A (zh) 一種高活性的ｈｐｋ１激酶抑制劑
CN114127080B (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
CN107922407A (zh) 呼吸道合胞病毒抑制剂
CN112209925A (zh) Ret选择性抑制剂及其制备方法和用途
TWI768781B (zh) 轉化生長因子－β受體抑制劑
WO2023169170A1 (zh) 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
CN119053596A (zh) 作为激酶抑制剂的杂环化合物、其组合物及使用方法
HK40040938B (zh) 稠环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20180302